Research programme: haematological disorders therapies - SelecoreAlternative Names: Thrombopoietin receptor agonists - Selecore; TPO-R agonists - Selecore
Latest Information Update: 18 May 2011
At a glance
- Originator Selecore
- Class Proteins
- Mechanism of Action Thrombopoietin stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Haematological disorders
Most Recent Events
- 07 Sep 2005 Preclinical trials in Haematological disorders in Germany (unspecified route)